Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(3):182-183; doi:10.1093/jnci/92.3.182
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Giannakakou, P.
Right arrow Articles by Fojo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannakakou, P.
Right arrow Articles by Fojo, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 3, 182-183, February 2, 2000
© 2000 Oxford University Press

EDITORIALS

Tubulin/Microtubules: Still a Promising Target for New Chemotherapeutic Agents

Paraskevi Giannakakou, Dan Sackett, Tito Fojo

Affiliations of authors: P. Giannakakou, T. Fojo, Medicine Branch, Division of Clinical Science, National Cancer Institute, Bethesda, MD; D. Sackett, Laboratory of Integrative and Medical Biophysics, National Institute of Child Health and Human Development, Bethesda.

Correspondence to: Tito Fojo, M.D., Ph.D., National Institutes of Health, Bldg. 10, Rm. 12N226, Bethesda, MD 20892.

Most investigators would agree that the ideal chemotherapeutic agent should be 1) directed at a validated target; 2) potent, preferably active at nanomolar or subnanomolar concentrations; 3) schedule independent, even active in noncycling cells; 4) active against drug-resistant cells; and 5) less toxic or ideally not toxic to normal cells. In this issue of the Journal, Leoni et al. (1) suggest that indanocine, a synthetic antimitotic indanone, possesses all of these properties. Further studies will be needed to prove this convincingly, but even if indanocine is not the ideal compound, one may . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
G. Kuznetsov, K. TenDyke, M. J. Towle, H. Cheng, J. Liu, J. P. Marsh, S. E.R. Schiller, M. R. Spyvee, H. Yang, B. M. Seletsky, et al.
Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin
Mol. Cancer Ther., October 1, 2009; 8(10): 2852 - 2860.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-M. Wang, L.-X. Hu, Z.-M. Liu, X.-F. You, S.-H. Zhang, J.-R. Qu, Z.-R. Li, Y. Li, W.-J. Kong, H.-W. He, et al.
N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6218 - 6227.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S.-W. Wang, S.-L. Pan, Y.-C. Huang, J.-H. Guh, P.-C. Chiang, D.-Y. Huang, S.-C. Kuo, K.-H. Lee, and C.-M. Teng
CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo
Mol. Cancer Ther., February 1, 2008; 7(2): 350 - 360.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
E. Vassal, C. Barette, X. Fonrose, R. Dupont, E. Sans-Soleilhac, and L. Lafanechere
Miniaturization and Validation of a Sensitive Multiparametric Cell-Based Assay for the Concomitant Detection of Microtubule-Destabilizing and Microtubule-Stabilizing Agents
J Biomol Screen, June 1, 2006; 11(4): 377 - 389.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
V. K.W. Wong, P. Chiu, S. S.M. Chung, L. M.C. Chow, Y.-Z. Zhao, B. B. Yang, and B. C.B. Ko
Pseudolaric Acid B, a Novel Microtubule-Destabilizing Agent That Circumvents Multidrug Resistance Phenotype and Exhibits Antitumor Activity In vivo
Clin. Cancer Res., August 15, 2005; 11(16): 6002 - 6011.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. N. Demidenko, D. Halicka, J. Kunicki, J. A. McCubrey, Z. Darzynkiewicz, and M. V. Blagosklonny
Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel
Cancer Res., May 15, 2005; 65(10): 4401 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Z. Chen, P. J. Merta, N.-H. Lin, S. K. Tahir, P. Kovar, H. L. Sham, and H. Zhang
A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth
Mol. Cancer Ther., April 1, 2005; 4(4): 562 - 568.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. K. Beuria, S. S. Krishnakumar, S. Sahar, N. Singh, K. Gupta, M. Meshram, and D. Panda
Glutamate-induced Assembly of Bacterial Cell Division Protein FtsZ
J. Biol. Chem., January 31, 2003; 278(6): 3735 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Alli, J. Bash-Babula, J.-M. Yang, and W. N. Hait
Effect of Stathmin on the Sensitivity to Antimicrotubule Drugs in Human Breast Cancer
Cancer Res., December 1, 2002; 62(23): 6864 - 6869.
[Abstract] [Full Text] [PDF]